|
|
About Eisai Inc.
Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care company that discovers, develops and markets products throughout the world. Established in 1995, we began marketing our first product in the United States in 1997 and have rapidly grown to become an integrated pharmaceutical business.
Eisai Inc. is one of only four companies in the United States ever to reach $1 billion in sales within just five years. In fiscal year 2008 (year ending March 31, 2009), Eisai Inc. achieved sales of nearly $3.7 billion.
Drawing on the R&D strengths of our global parent company, Eisai Inc. focuses on three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.
Eisai Inc. employs more than 2,700 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, N.C., its discovery research center based in Andover, MA, its pharmaceutical manufacturing machinery facility in Allendale, NJ, at Morphotek, a wholly-owned subsidiary that specializes in the discovery and development of therapeutic monoclonal antibodies (mAbs), and in the field. We are expanding our capabilities in sales, marketing, manufacturing, product research, management and training. And as the company grows, we are continuing to develop the areas of financial and human resources, information services management, business development, and medical, legal and public affairs. We invite you to apply online!
 Printer Friendly Version
|
|
